Literature DB >> 9071813

TGF-beta receptors and signal transduction.

K Miyazono1.   

Abstract

TGF-beta inhibits the growth of many cell types, including hematopoietic cells and lymphocytes. TGF-beta transduces signals through two different types of serine/threonine kinase receptors, type I (T beta R-I) and type II (T beta R-II). T beta R-II is a primary binding protein for the ligands, and T beta R-I is an effector protein, which determines the specificity of signals. Type III receptor (betaglycan) and endoglin play more indirect roles; i.e. delivery of ligands to the signaling receptors. Various molecules, including farnesyl transferase-alpha, Mothers against dpp (Mad)-related proteins, and a novel MAPKKK (TAK1), have been suggested to participate in the signal transduction of TGF-beta receptors. TGF-beta receptors and Mad-related proteins have been found to act as tumor suppressor genes in various tumors, including colorectal cancers and T-cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9071813     DOI: 10.1016/s0925-5710(96)00542-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  12 in total

Review 1.  Growth regulatory factors and bone.

Authors:  G R Mundy; D Chen; M Zhao; S Dallas; C Xu; S Harris
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

2.  Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling.

Authors:  Shiri Kfir; Marcelo Ehrlich; Ayelet Goldshmid; Xuedong Liu; Yoel Kloog; Yoav I Henis
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

3.  Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface.

Authors:  Jin-Sung Chung; Lisa H Shiue; Madeleine Duvic; Amit Pandya; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Blood       Date:  2011-01-20       Impact factor: 22.113

Review 4.  Differentiation, apoptosis, and function of human immature and mature myeloid cells: intracellular signaling mechanism.

Authors:  Akira Yuo
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

5.  Consequences of epithelial or stromal TGFβ1 depletion in the mammary gland.

Authors:  David H Nguyen; Haydeliz Martinez-Ruiz; Mary Helen Barcellos-Hoff
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-05-17       Impact factor: 2.673

6.  Distinct roles of Smad pathways and p38 pathways in cartilage-specific gene expression in synovial fibroblasts.

Authors:  Hiroaki Seto; Satoshi Kamekura; Toshiki Miura; Aiichiro Yamamoto; Hirotaka Chikuda; Toru Ogata; Hisatada Hiraoka; Hiromi Oda; Kozo Nakamura; Hisashi Kurosawa; Ung-Il Chug; Hiroshi Kawaguchi; Sakae Tanaka
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

7.  Altered expression of Smad proteins in T or NK-cell lymphomas.

Authors:  Jai Hyang Go
Journal:  Cancer Res Treat       Date:  2008-12-31       Impact factor: 4.679

8.  Preparation and identification of anti-transforming growth factor beta1 U1 small nuclear RNA chimeric ribozyme in vitro.

Authors:  Ju-Sheng Lin; Yu-Hu Song; Xin-Juan Kong; Bin Li; Nan-Zhi Liu; Xiao-Li Wu; You-Xin Jin
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

9.  High-glucose levels and elastin degradation products accelerate osteogenesis in vascular smooth muscle cells.

Authors:  Aditi Sinha; Naren R Vyavahare
Journal:  Diab Vasc Dis Res       Date:  2013-06-10       Impact factor: 3.291

10.  A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate.

Authors:  S Bhattacharyya; W Ishida; M Wu; M Wilkes; Y Mori; M Hinchcliff; E Leof; J Varga
Journal:  Oncogene       Date:  2009-01-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.